Author + information
Study of the effect of testosterone on the main risk factors (FR) of cardiovascular diseases (CVD) in men with hypogonadism and high cardiovascular risk.
The study included 40 men aged 30-59 with hypogonadism and high cardiovascular risk on a SCORE (5% or more). Patients were divided into 2 groups: the main group received testosterone injections according to the standard scheme. The duration of the study was 30 weeks. Before and after the study, all men evaluated the erectile function and the dynamics of total and free testosterone in the blood sample. In addition, changes in blood pressure, waist circumference, lipid and glucose parameters, as well as the level of total cardiovascular risk were estimated.
Against the background of the course therapy with testosterone, in contrast to the control group, there was an increase in the concentration of total testosterone by 30% and free testosterone by 57%, which was accompanied by a significant improvement in erectile function by 12%. In both groups, for 30 weeks, the mean levels of cholesterol and glucose levels did not change significantly. Course testosterone therapy led to a significant decrease in the level of total cholesterol by 11%, LDL cholesterol by 12%, triglyceride levels decreased by 22% (p <0.01), and there were no changes in the control group. It is known that the waist circumference is an important indicator of abdominal obesity, therapy with testosterone resulted in a decrease by an average of 1.7 cm. Overall, testosterone therapy reduced the risk of total cardiovascular risk by 30%, which is significantly significant compared to with a control group.
Thus, testosterone exchange therapy in men with hypogonadism and high cardiovascular risk not only normalizes the level of total and free testosterone and improves erectile function, but positively affects the main risk factors and the level of total cardiovascular risk.